A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06384261
- Locations
- ๐บ๐ธ
The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
๐จ๐ฆTom Baker Cancer Center-Alberta Health Services - University of Calgary, Calgary, Alberta, Canada
๐จ๐ฆStollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta, Edmonton, Alberta, Canada
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04241549
- Locations
- ๐ฏ๐ต
Fukushima Medical University Hospital, Fukushima, Japan
๐ฏ๐ตOsaka City General Hospital, Osaka, Japan
๐ฏ๐ตUniversity of Fukui Hospital, Yoshida, Japan
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04150887
- Locations
- ๐ต๐ฑ
Szpital Uniwersytecki w Krakowie, Krakow, Poland
๐จ๐ญKantonsspital St.Gallen, St. Gallen, Switzerland
๐ต๐ฑWojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04023526
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Center, Jerusalem, Israel
๐ท๐บOncologic Dispensary No.2, Sochi, Russian Federation
๐ท๐บKomi Republic Oncology dispensary, Syktyvkar, Russian Federation
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03030612
A Study of ARGX-110 in Participants With Advanced Malignancies
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01813539